EGFR and neoplasm: The four radiomics features model, built using a Random Forest algorithm to diagnose anti-EGFR treatment-sensitive tumors, outperformed both KRAS-mutational status at baseline (AUC = 0.67, p < 0.001) and 8-week tumor shrinkage (RECIST 1.1-like unidimensional tumor shrinkage) [31].